Overview
myNEO Therapeutics' ImmunoEngine platform combines immunology expertise with AI-driven technologies for personalized neoantigen discovery in cancer vaccines and T-cell therapies, mRNA codon optimization, ADA risk prediction, and multi-epitope construct design. The company serves vaccine developers, biologics innovators, and pharma partners, and offers a proprietary asset library of immunotherapy targets for partnering and licensing.
Media & appearances
- WintercircusYouTubeEngineering Leadership Program | From engineer to leaderLore Van Oudenhove recently transitioned from a developer role to CTO there and applies program learnings to its processes.
Leadership & org chart
In the news
- How do we get new, innovative therapies to patients? And how do we do this faster? 🧪 Belgium has it all when it comes to groundbreaking treatments: strong science, clinical expertise and a #healthcare ecosystem capable of contributing to the development of innovative therapies. 🏥 Yet new treatments do not always reach Belgian patients, or access is delayed. 🇧🇪 At Science for health, Patricia van Dijck will open a discussion on how #Belgium can become a more compelling launch country and translate its strengths into faster and
- Busy conference season ahead! Our team will be heading to events across Europe this autumn. Let’s connect and talk!
- Exciting milestone for myNEO Therapeutics! We are pleased to announce that Arcturus Therapeutics has entered into a definitive agreement to acquire myNEO. Since 2024, our teams have worked closely together around a shared vision: combining advanced AI capabilities with next generation mRNA innovation. We believe this combination creates a powerful foundation to accelerate discovery, strengthen target identification capabilities, and bring innovative therapies to patients faster. This achievement is the result of the hard work,
- Turning innovation into impact for patients. 🤝 Together with Odimma Therapeutics, we’re combining our AI-driven neoantigen discovery pipeline with tailor-made synthetic DNA technology for personalized treatment of cancer patients. Let's move precision oncology forward! #personalizedvaccine #neoantigendiscovery
- Moving cancer research forward, together! 💙 Last Thursday, the myNEO team took some time away from our daily work to connect, recharge and strengthen the team behind our mission. Because the best progress happens when we move forward together. #myNEO #TeammyNEO #MovingCancerResearchForward #TeamBuilding
- It's not often that the good people of SynBioBeta mention work that one of our portfolio companies has done! A very big congratulations to the myNEO Therapeutics team!!
- Did you know? #myneoacademy #education #tcellcheckpoints
- 𝐌𝐨𝐫𝐞 𝐞𝐩𝐢𝐭𝐨𝐩𝐞𝐬 𝐝𝐨 𝗻𝗼𝘁 𝐚𝐥𝐰𝐚𝐲𝐬 𝐦𝐚𝐤𝐞 𝐚 𝐛𝐞𝐭𝐭𝐞𝐫 𝐯𝐚𝐜𝐜𝐢𝐧𝐞. 𝐁𝐞𝐭𝐭𝐞𝐫 𝐜𝐨𝐧𝐬𝐭𝐫𝐮𝐜𝐭 𝐝𝐞𝐬𝐢𝐠𝐧 𝐝𝐨𝐞𝐬. Designing an optimal multi-epitope construct means balancing dozens of parameters simultaneously. That's why we built 𝗺𝘆𝗖𝗢𝗡𝗦𝗧𝗥𝗨𝗖𝗧 within an 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝘃𝗲 𝘃𝗶𝘀𝘂𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, making complex construct optimization transparent, interpretable, and easy to explore. The platform enables: 🔹Exploration of the complete construct optimization
Alumni 1 went on to found or lead
Christophe Van HuffelBusiness Growth Adviser→Co-Founder and CSO at OncoRNA
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.